Eli Lilly and Company (LLY)

$1,213.91 +22.17 (1.86%)
Market Cap 1,143.19B
Revenue (ttm) 65.18B
Net Income (ttm) 20.64B
EPS (ttm) N/A
PE Ratio 40.51
Forward PE 33.35
Profit Margin 31.67%
Debt to Equity Ratio 1.26
Volume 3,297,400
Avg Vol 3,411,884
Day's Range N/A - N/A
Shares Out 941.74M
Stochastic %K 85%
Beta 0.51
Analysts Strong Sell
Price Target $1,248.82

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
IndyOne
IndyOne Jul. 4 at 5:16 PM
$MRNA Trade what you see, 1 month chart for Moderna. Buy, Buy some more. HOLD. A lot of people sold $NVDA after a double in the early days. Regret. From the bottom, NVIDIA is up 6,494 x. A $1,000 investment in NVIDIA at the bottom is now worth $6,494,333. Unfortunately NVIDIA may now have "big company disease". The NVIDIA market cap is $4.7 trillion. USA GDP is $31.9 trillion - the run is done? Moderna market cap is only $31 billion. Plenty of runway left, for instance, $LLY is $1.1 trillion. Moderna's Cancer, Respiratory, and Rare Disease empire forming now. This new franchise and platform could hold a 35 times your investment from here. Some say mRNA is as big as GLPs. Diversify into Moderna.
0 · Reply
grampslol
grampslol Jul. 4 at 4:31 PM
$MNKD home to afrezza dpi inhaled prandial insulin ... an American flop since 2014 ... lol ... $LLY $NVO $SPY #afizzle
0 · Reply
TalkMarkets
TalkMarkets Jul. 4 at 3:15 PM
The Market Looks Calm. That's Exactly What Worries Me. $IWM $LLY $QQQ $SPY $STRC https://talkmarkets.com/article/the-market-looks-calm-thats-exactly-what-worries-me-1783157231
0 · Reply
Achandler787
Achandler787 Jul. 4 at 2:28 PM
$CABA $LLY
0 · Reply
stockro1
stockro1 Jul. 4 at 2:28 PM
$IXHL The market has a habit of mispricing companies when the story changes faster than the valuation. I think that’s happening here. • Targeting one of the world’s largest unmet medical markets (Obstructive Sleep Apnoea) • Positive Phase 2 efficacy • Strong balance sheet, minimal debt • Multiple catalysts ahead • Small share count • Valuation that still looks modest if development succeeds This is now an execution story. Today’s valuation appears to price in far more failure than success. Watching for: ✔️ First patient dosed ✔️ Clinical progress ✔️ Institutional buying ✔️ Strategic partnerships The biggest gains often come before consensus catches up. Do your own research. $IXHL $VKTX $ALT $HIMS $LLY
3 · Reply
clan
clan Jul. 4 at 2:16 PM
$MNKD 🇺🇲🦅🇺🇲 As American as Afrezza and Mannkind! #afrezza Inhalable meatime insulin for diabetics. ❤️🇺🇲❤️ No needles! 🚫💉 $LLY $NVO 👀 $SPY
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
AXLFI_HQ
AXLFI_HQ Jul. 4 at 1:19 PM
$LLY FDA regulatory approvals are expanding for healthcare innovations including novel antibiotics, immunotherapies, and precision diagnostics, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 4 at 12:45 PM
$REGN $VRTX $NVO $ABBV $LLY From obesity drugs and diabetes treatments to CRISPR gene editing, mRNA cancer vaccines, biologics, and rare disease therapies, these 5 biotech stocks could be among the most exciting healthcare stocks to watch in today’s market. https://biotechhealthx.com/biotech-news/5-biotech-stocks-that-could-turn-medicine-into-wall-streets-next-gold-rush/
0 · Reply
LLYBULL
LLYBULL Jul. 4 at 12:16 PM
$LLY LLY's Foundayo pill actual numbers are twice of what is being reported as direct channel numbers are not considered in reporting.
0 · Reply
Latest News on LLY
AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why

2026-07-02T09:13:46.000Z - 2 days ago

AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why

NVDA

Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings

2026-07-01T16:04:55.000Z - 3 days ago

Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings

RY

Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results

Jul 1, 2026, 10:23 AM EDT - 3 days ago

Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results

Eli Lilly Stock (LLY) Retreats as China Threats Emerge

2026-06-30T18:55:11.000Z - 3 days ago

Eli Lilly Stock (LLY) Retreats as China Threats Emerge

Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement

2026-06-30T09:50:28.000Z - 4 days ago

Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement

Medicare will start covering obesity drugs for the first time. Here's what patients should know

Jun 30, 2026, 5:00 AM EDT - 4 days ago

Medicare will start covering obesity drugs for the first time. Here's what patients should know

NVO

China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug

Jun 30, 2026, 1:57 AM EDT - 4 days ago

China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Jun 30, 2026, 12:00 AM EDT - 4 days ago

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities

2026-06-29T19:44:36.000Z - 4 days ago

FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

Jun 29, 2026, 3:03 PM EDT - 4 days ago

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

REGN

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

2026-06-29T19:00:12.000Z - 4 days ago

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

AMRX REGN

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Jun 29, 2026, 2:50 PM EDT - 4 days ago

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

REGN

Eli Lilly Stock (LLY) Hits All-Time High as Weight-Loss Drug Sales Accelerate

2026-06-29T14:34:54.000Z - 5 days ago

Eli Lilly Stock (LLY) Hits All-Time High as Weight-Loss Drug Sales Accelerate

NVO

GAME CHANGER: Eli Lilly launches $50 Medicare GLP-1 program

Jun 28, 2026, 10:00 PM EDT - 5 days ago

GAME CHANGER: Eli Lilly launches $50 Medicare GLP-1 program

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

Jun 28, 2026, 8:00 AM EDT - 6 days ago

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

NVO

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 7 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE JNJ MRNA SNY XBI

Here’s Why Eli Lilly Stock (LLY) Is Up 6% Today

2026-06-26T14:49:53.000Z - 8 days ago

Here’s Why Eli Lilly Stock (LLY) Is Up 6% Today

GLP-1s linked to smell and taste impairment in diabetes patients

Jun 26, 2026, 10:45 AM EDT - 8 days ago

GLP-1s linked to smell and taste impairment in diabetes patients

NVO

Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

Jun 26, 2026, 10:08 AM EDT - 8 days ago

Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

NVO

Eli Lilly’s Jaypirca recommended by CHMP for approval in EU

2026-06-26T11:20:11.000Z - 8 days ago

Eli Lilly’s Jaypirca recommended by CHMP for approval in EU

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Jun 26, 2026, 7:16 AM EDT - 8 days ago

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Eli Lilly announces more details of Medicare GLP-1 Bridge program

2026-06-25T10:55:49.000Z - 9 days ago

Eli Lilly announces more details of Medicare GLP-1 Bridge program

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

Jun 25, 2026, 6:45 AM EDT - 9 days ago

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

Eli Lilly price target raised to $1,232 from $1,119 at Leerink

2026-06-25T10:06:09.000Z - 9 days ago

Eli Lilly price target raised to $1,232 from $1,119 at Leerink

Controversy Erupts Over Report Trump Has Early Access to Eli Lilly (LLY) Weight-Loss Drug

2026-06-24T14:40:06.000Z - 10 days ago

Controversy Erupts Over Report Trump Has Early Access to Eli Lilly (LLY) Weight-Loss Drug

NYT

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Jun 24, 2026, 8:45 AM EDT - 10 days ago

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says

Jun 24, 2026, 2:36 AM EDT - 10 days ago

China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly

Jun 23, 2026, 9:38 PM EDT - 10 days ago

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly

How Eli Lilly Became a $1 Trillion Company

Jun 23, 2026, 1:34 PM EDT - 11 days ago

How Eli Lilly Became a $1 Trillion Company

Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Jun 23, 2026, 12:10 PM EDT - 11 days ago

Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Fund manager names 3 non-AI stocks to own as Intel, AMD sink amid broader tech rout

Jun 23, 2026, 11:51 AM EDT - 11 days ago

Fund manager names 3 non-AI stocks to own as Intel, AMD sink amid broader tech rout

GEV

Lilly declares third-quarter 2026 dividend

Jun 22, 2026, 11:00 AM EDT - 12 days ago

Lilly declares third-quarter 2026 dividend

Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries

Jun 22, 2026, 5:30 AM EDT - 12 days ago

Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries

NVO

Ozempic Linked To Lower Risk Of Violence In New Study

Jun 17, 2026, 11:45 AM EDT - 17 days ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN NVO TWST

Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

Jun 16, 2026, 1:06 PM EDT - 18 days ago

Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

Jun 15, 2026, 12:30 PM EDT - 19 days ago

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Jun 14, 2026, 3:15 AM EDT - 20 days ago

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

The Next Phase Of The Obesity Drug Race

Jun 13, 2026, 2:00 PM EDT - 21 days ago

The Next Phase Of The Obesity Drug Race

GPCR NVO

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Jun 13, 2026, 11:15 AM EDT - 21 days ago

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Drugmakers race to find a place in the next wave of obesity drugs

Jun 13, 2026, 8:00 AM EDT - 21 days ago

Drugmakers race to find a place in the next wave of obesity drugs

AMGN NVO AZN

MU, GOOGL, LLY & Other Stocks Andrew Arons is Watching This Summer

Jun 11, 2026, 2:00 PM EDT - 23 days ago

MU, GOOGL, LLY & Other Stocks Andrew Arons is Watching This Summer

GOOG GOOGL MU

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 23 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Jun 11, 2026, 6:03 AM EDT - 23 days ago

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

NVO

Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Jun 10, 2026, 6:02 AM EDT - 24 days ago

Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

Jun 9, 2026, 6:18 PM EDT - 24 days ago

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

Jun 9, 2026, 6:06 PM EDT - 24 days ago

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

HUM MDT UNH

Eli Lilly and Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 3:20 PM EDT - 24 days ago

Eli Lilly and Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Is It Too Late To Buy The Rally In Eli Lilly Stock?

Jun 9, 2026, 2:03 PM EDT - 25 days ago

Is It Too Late To Buy The Rally In Eli Lilly Stock?

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 25 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ MRK NVO PFE

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

Jun 9, 2026, 4:00 AM EDT - 25 days ago

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 25 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY MRK PFE RDW UTHR XBI

Use of GLP-1 drugs early in pregnancy should not cause alarm

Jun 8, 2026, 5:05 PM EDT - 25 days ago

Use of GLP-1 drugs early in pregnancy should not cause alarm

NVO

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Jun 8, 2026, 2:30 PM EDT - 26 days ago

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

Jun 8, 2026, 1:50 PM EDT - 26 days ago

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Jun 8, 2026, 10:30 AM EDT - 26 days ago

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

NVO

Monday's Morning Movers: MU & SNDK PT Hikes, LLY Foundayo Delivers

Jun 8, 2026, 10:30 AM EDT - 26 days ago

Monday's Morning Movers: MU & SNDK PT Hikes, LLY Foundayo Delivers

SNDK MU

Lilly shares jump as analysts see retatrutide data extending obesity market edge

Jun 8, 2026, 7:06 AM EDT - 26 days ago

Lilly shares jump as analysts see retatrutide data extending obesity market edge

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Jun 8, 2026, 6:16 AM EDT - 26 days ago

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Jun 8, 2026, 5:44 AM EDT - 26 days ago

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

Jun 8, 2026, 5:35 AM EDT - 26 days ago

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Jun 7, 2026, 11:00 AM EDT - 27 days ago

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Eli Lilly and Company Transcript: American Diabetes Association (ADA) 86th Scientific Sessions

Jun 6, 2026, 7:00 PM EDT - 27 days ago

Eli Lilly and Company Transcript: American Diabetes Association (ADA) 86th Scientific Sessions

Eli Lilly and Company Slides: American Diabetes Association (ADA) 86th Scientific Sessions

Jun 6, 2026, 7:00 PM EDT - 27 days ago

Eli Lilly and Company Slides: American Diabetes Association (ADA) 86th Scientific Sessions

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Jun 6, 2026, 2:53 PM EDT - 27 days ago

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Jun 6, 2026, 2:34 PM EDT - 27 days ago

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

IndyOne
IndyOne Jul. 4 at 5:16 PM
$MRNA Trade what you see, 1 month chart for Moderna. Buy, Buy some more. HOLD. A lot of people sold $NVDA after a double in the early days. Regret. From the bottom, NVIDIA is up 6,494 x. A $1,000 investment in NVIDIA at the bottom is now worth $6,494,333. Unfortunately NVIDIA may now have "big company disease". The NVIDIA market cap is $4.7 trillion. USA GDP is $31.9 trillion - the run is done? Moderna market cap is only $31 billion. Plenty of runway left, for instance, $LLY is $1.1 trillion. Moderna's Cancer, Respiratory, and Rare Disease empire forming now. This new franchise and platform could hold a 35 times your investment from here. Some say mRNA is as big as GLPs. Diversify into Moderna.
0 · Reply
grampslol
grampslol Jul. 4 at 4:31 PM
$MNKD home to afrezza dpi inhaled prandial insulin ... an American flop since 2014 ... lol ... $LLY $NVO $SPY #afizzle
0 · Reply
TalkMarkets
TalkMarkets Jul. 4 at 3:15 PM
The Market Looks Calm. That's Exactly What Worries Me. $IWM $LLY $QQQ $SPY $STRC https://talkmarkets.com/article/the-market-looks-calm-thats-exactly-what-worries-me-1783157231
0 · Reply
Achandler787
Achandler787 Jul. 4 at 2:28 PM
$CABA $LLY
0 · Reply
stockro1
stockro1 Jul. 4 at 2:28 PM
$IXHL The market has a habit of mispricing companies when the story changes faster than the valuation. I think that’s happening here. • Targeting one of the world’s largest unmet medical markets (Obstructive Sleep Apnoea) • Positive Phase 2 efficacy • Strong balance sheet, minimal debt • Multiple catalysts ahead • Small share count • Valuation that still looks modest if development succeeds This is now an execution story. Today’s valuation appears to price in far more failure than success. Watching for: ✔️ First patient dosed ✔️ Clinical progress ✔️ Institutional buying ✔️ Strategic partnerships The biggest gains often come before consensus catches up. Do your own research. $IXHL $VKTX $ALT $HIMS $LLY
3 · Reply
clan
clan Jul. 4 at 2:16 PM
$MNKD 🇺🇲🦅🇺🇲 As American as Afrezza and Mannkind! #afrezza Inhalable meatime insulin for diabetics. ❤️🇺🇲❤️ No needles! 🚫💉 $LLY $NVO 👀 $SPY
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
AXLFI_HQ
AXLFI_HQ Jul. 4 at 1:19 PM
$LLY FDA regulatory approvals are expanding for healthcare innovations including novel antibiotics, immunotherapies, and precision diagnostics, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 4 at 12:45 PM
$REGN $VRTX $NVO $ABBV $LLY From obesity drugs and diabetes treatments to CRISPR gene editing, mRNA cancer vaccines, biologics, and rare disease therapies, these 5 biotech stocks could be among the most exciting healthcare stocks to watch in today’s market. https://biotechhealthx.com/biotech-news/5-biotech-stocks-that-could-turn-medicine-into-wall-streets-next-gold-rush/
0 · Reply
LLYBULL
LLYBULL Jul. 4 at 12:16 PM
$LLY LLY's Foundayo pill actual numbers are twice of what is being reported as direct channel numbers are not considered in reporting.
0 · Reply
TomMac64
TomMac64 Jul. 4 at 10:29 AM
$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !
0 · Reply
LLYBULL
LLYBULL Jul. 4 at 9:10 AM
$LLY HSBC are top crooks and top manipulators
1 · Reply
LLYBULL
LLYBULL Jul. 4 at 8:55 AM
$LLY Custom Markets insights projects CAGR of 11.62% for TAM of Obesity and Diabetes. 2026 is at 115B. 2035 is at 310B. Not sure where HSBC came up with numbers saying TAM of 130B by 2032.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
Investor203
Investor203 Jul. 4 at 5:39 AM
$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else
0 · Reply
Jaxson25
Jaxson25 Jul. 3 at 3:39 PM
$LLY lets get that 600
0 · Reply
Hooooooold
Hooooooold Jul. 3 at 1:37 PM
$NVO $LLY FOUNDAYO IS GAINING! As nvo investor im worried now! At this rate foundayo is going to overtake wegovy oral in 2086!
3 · Reply
clan
clan Jul. 3 at 1:13 PM
$MNKD 🇺🇲 Inhalable mealtime insulin! Who knew?!? 🚫💉 #inhalemyinsulin 😲🤯 #Afrezza For the good of all diabetic Mannkind $LLY $SPY $NVO 🇺🇲💪
1 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 3 at 11:29 AM
$LLY continue rally against 4.29.206 low as expected in 6.11.2026 update against 1052.2 low It should remain supported in pullback in 3, 7 or 11 swings to continue rally above 1362.4 or higher. Buyers should wait for pullback to re-enter the longs. #Elliottwave #LLY
0 · Reply
michele1208
michele1208 Jul. 3 at 7:29 AM
New Symphony prescription data for $NVO and $LLY • Oral Wegovy: 115,591 prescriptions in week 26 vs. 116,767 in week 25. This marks the second consecutive weekly decline, though prescriptions remain close to the all-time high of 119,227 reached in week 24. • Foundayo: 5,501 prescriptions vs. 5,167 the previous week, continuing its gradual growth. It's worth noting that Symphony does not include prescriptions filled through online pharmacies, telehealth platforms, or NovoCare. Novo recently said Oral Wegovy had surpassed 3 million U.S. prescriptions just five months after launch, while Symphony has captured about 2.0 million prescriptions over the same period.
1 · Reply
SonGoku
SonGoku Jul. 3 at 2:30 AM
I prolly should have been paying more attention to $LLY and not underestimating its giant MOAT..
0 · Reply